540 results on '"Cercek, A."'
Search Results
2. Combined Hepatic Arterial Infusion Pump and Systemic Chemotherapy in the Modern Era for Chemotherapy-Naive Patients with Unresectable Colorectal Liver Metastases
- Author
-
Verheij, Floris S., Kuhlmann, Koert F. D., Silliman, Danielle R., Soares, Kevin C., Kingham, T. Peter, Balachandran, Vinod P., Drebin, Jeffrey A., Wei, Alice C., Jarnagin, William R., Cercek, Andrea, Kok, Niels F. M., Kemeny, Nancy E., and D’Angelica, Michael I.
- Published
- 2023
- Full Text
- View/download PDF
3. Neoplasia risk in patients with Lynch syndrome treated with immune checkpoint blockade
- Author
-
Harrold, Emily C., Foote, Michael B., Rousseau, Benoit, Walch, Henry, Kemel, Yelena, Richards, Allison L., Keane, Fergus, Cercek, Andrea, Yaeger, Rona, Rathkopf, Dana, Segal, Neil H., Patel, Zalak, Maio, Anna, Borio, Matilde, O’Reilly, Eileen M., Reidy, Diane, Desai, Avni, Janjigian, Yelena Y., Murciano-Goroff, Yonina R., Carlo, Maria I., Latham, Alicia, Liu, Ying L., Walsh, Michael F., Ilson, David, Rosenberg, Jonathan E., Markowitz, Arnold J., Weiser, Martin R., Rossi, Anthony M., Vanderbilt, Chad, Mandelker, Diana, Bandlamudi, Chaitanya, Offit, Kenneth, Berger, Michael F., Solit, David B., Saltz, Leonard, Shia, Jinru, Diaz, Jr., Luis A., and Stadler, Zsofia K.
- Published
- 2023
- Full Text
- View/download PDF
4. Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer
- Author
-
Ambrosini, M., Rousseau, B., Manca, P., Artz, O., Marabelle, A., André, T., Maddalena, G., Mazzoli, G., Intini, R., Cohen, R., Cercek, A., Segal, N.H., Saltz, L., Varghese, A.M., Yaeger, R., Nusrat, M., Goldberg, Z., Ku, G.Y., El Dika, I., Margalit, O., Grinshpun, A., Murtaza Kasi, P., Schilsky, R., Lutfi, A., Shacham-Shmueli, E., Khan Afghan, M., Weiss, L., Westphalen, C.B., Conca, V., Decker, B., Randon, G., Elez, E., Fakih, M., Schrock, A.B., Cremolini, C., Jayachandran, P., Overman, M.J., Lonardi, S., and Pietrantonio, F.
- Published
- 2024
- Full Text
- View/download PDF
5. Extrahepatic perfusion and incomplete hepatic perfusion after hepatic arterial infusion pump implantation: incidence and clinical implications
- Author
-
Filipe, Wills F., Buisman, Florian Buismanz, Koerkamp, Bas Groot, Grunhagen, Dirk J., Homs, Marjolein Y.V., Verhoef, Cornelis, Moelker, Adriaan, Graven, Laura, Franssen, Stijn, Gobardhan, Paul D., Loosveld, Olaf J.L., Pool, Stefan, Mieog, J. Sven D., Speetjens, Frank M., Rietbergen, Daphne D.D., Burgmans, Mark C., Doornesbosch, Pascal G., Patijn, Gijs A., de Groot, Jan Willem B., Meier, Mark A.J., Oostdijk, Ad H.J., Boluis, Karen, Grootscholten, Cecile, klompenhouwer, Elizabeth G., Kok, Niels F.M., kuhlmann, Koert, F.D., Krul, Myrtle F., Versleijen, Michelle W.J., Bruijnen, Rutger C.G., Hagendoorn, Jroen, Lam, Marnix G.E.H., Roodhart, Jeanine M.L., Bennink, Roel J., van Delden, Otto M., Swijnenburg, Rutger-Jan, Buffart, Tineke E., Borel Rinkes, Inne H.M., Cercek, Andrea, Kemeny, Nancy E., Peter Kingham, T., D’Angelica, Michael, van Bommel, Christian P.H., van Doorn, Leni, Ayez, Ninos, Vermaas, Maarten, Nieuwenhuijse, Vincent B., Buisman, Florian E., Grünhagen, Dirk J., Bolhuis, Karen, Doornebosch, Pascal G., Hagendoorn, Jeroen, Harmsen, Paul, Klompenhouwer, Elizabeth G., Outmani, Loubna, Swijnenburg, Rutger Jan, Kuhlmann, Koert F.D., and Groot Koerkamp, Bas
- Published
- 2024
- Full Text
- View/download PDF
6. LANDMARK comparison of early outcomes of newer-generation Myval transcatheter heart valve series with contemporary valves (Sapien and Evolut) in real-world individuals with severe symptomatic native aortic stenosis: a randomised non-inferiority trial
- Author
-
Siqueira, Dimytri, Pinto, Ibraim, Cervone, Alberto, Assef, Jorge, Vilela, Andrea, Paladino, Antonio, Ramos, Auristela, Rezende, Mariana, Ghorayeb, Samira, Braga Silva, Tacianne Rolemberg, Gjorgjievska, Savica, Hadzibegovic, Irzal, Jurin, Ivana, Sipic, Tomislav, Pavlovic, Nikola, Rudez, Igor, Manola, Sime, GALLET DE SAINT-AURIN, Romain, BOUKANTAR, Madjid, NICOLAS, Eroan, ENNEZAT, Pierre Valdimir, URIEN, Jean Marie, Vincent, Flavien, Delhaye, Cedric, Denimal, Tom, Cosenza, Alessandro, Pamart, Thibault, Porouchani, Sina, Pontana, Francois, Montaigne, David, Balmette, Vincent, Bechiri, Mohamed, Chen, Elisabeth, Janah, Dany, Renker, Matthias, Westermann, Dirk, Valina, Christian, Ferenc, Miroslaw, Löffelhardt, Nikolaus, Rahimi, Faridun, Breitbart, Philipp, Franke, Kilian, Czerny, Martin, Diab, Nawras, Sick, Peter, Adeishvili, Medea, Mangner, Norman, Haussig, Stephan, Sveric, Krunuslav, Crusius, Lisa, Roehlig, Marie, Koliastasis, Leonidas, Drakopoulou, Maria, Katsaros, Odysseas, Ktenopoulos, Nikolaos, Ioanniadis, Andreas, Evangelou, Sotirios, Ninios, Ilias, Molnar, Levente, Papp, Roland, Arnold-Béla, Ferencz, Demeterné Kiss, Orsolya, Nagy, Andrea, Czimbalmos, Csilla, Pellegrinni, Dario, Montonati, Carolina, Pellicano, Mariano, Guagliumi, Giulio, Tespili, Maurizio, Barbara, Bellini, Filippo, Russo, Marco, Ancona, Ciro, Vella, Luca, Ferri, Eustachio, Agricola, Giacomo, Ingallina, Cannone, Gaspare, Brambilla, Nedy, Testa, Luca, Avondo, Stefano, Valvo, Roberto, Clarke, Robin, Fish, Mandy, Kosowski, Michal, Krawczyk, Magdalena, Kubler, Piotr, Kotwica, Tomasz, Teles, Rui, Gonçalves, Pedro, Raposo, Luis, Brito, Joã, Leal, Silvio, Freitas, Pedro, Ribeiras, Regina, Poliacikova, Petra, Mihailovic, Peter Marko, Terseglav, Simon, Steblovnik, Klemen, Cercek, Miha, Vitez, Luka, Sustersic, Miha, Kovac, Ana, Kogoj, Polonca, Dimitrovska, Ljupka, Arana, J.Raul Delgado, Martinez, Sandra Santos, Dieguez, Alfredo Redondo, Barrero, Alejandro, Gonzalez-Bartol, Esther, Aristizabal, Cristhian, Frutos, Ana Serrador, Luna, Juan Pablo Sanchez, Gomez, Mario Garcia, Gabella, Tania Rodriguez, Nelson, Verónica Quevedo, Medina, Jose Novoa, Ojeda, Soledad, de Lezo, Javier Suarez, Romero, Miguel, Gonzalez-Manzanares, Rafael, Alvarado, Marco, Mesa, Dolores, Perea, Jorge, Petursson, Petur, Alchay, Monér, Andréen, Sofie, Gameren, Menno Van, Heijer, Peter den, Meuwissen, Martijn, CHENG, JIN M., Vos, Jeroen, Schölzel, B.E., Simsek, C, Hubbers, S, Van den Branden, Ben J.L., Stens, NA, Versteeg, GAA, Rooijakkers, MJP, Gehlmann, HR, Verkroost, MWA, Geuzebroek, GSC, Van Wely, MH, Van Geuns, RJ, van Nunen, LX, van Garsse, LAFM, Timmers, L, ten Berg, Jurrien, Kraaijeveld, A.O., Dickinson, M.G., Dessing, T.C., Mokhles, M.M., Baumbach, Andreas, van Royen, Niels, Amat-Santos, Ignacio J, Hudec, Martin, Bunc, Matjaz, Ijsselmuiden, Alexander, Laanmets, Peep, Unic, Daniel, Merkely, Bela, Hermanides, Renicus S, Ninios, Vlasis, Protasiewicz, Marcin, Rensing, Benno J W M, Martin, Pedro L, Feres, Fausto, De Sousa Almeida, Manuel, van Belle, Eric, Linke, Axel, Ielasi, Alfonso, Montorfano, Matteo, Webster, Mark, Toutouzas, Konstantinos, Teiger, Emmanuel, Bedogni, Francesco, Voskuil, Michiel, Pan, Manuel, Angerås, Oskar, Kim, Won-Keun, Rothe, Jürgen, Kristić, Ivica, Peral, Vicente, Garg, Scot, Elzomor, Hesham, Tobe, Akihiro, Morice, Marie-Claude, Onuma, Yoshinobu, Soliman, Osama, and Serruys, Patrick W
- Published
- 2024
- Full Text
- View/download PDF
7. Pharmaceutical Agents as Potential Drivers in the Development of Early-Onset Colorectal Cancer: Case-Control Study
- Author
-
Irit Ben-Aharon, Ran Rotem, Cheli Melzer-Cohen, Gilad Twig, Andrea Cercek, Elizabeth Half, Tal Goshen-Lago, Gabriel Chodik, and David Kelsen
- Subjects
Public aspects of medicine ,RA1-1270 - Abstract
BackgroundThe incidence of early-onset colorectal cancer (EOCRC) rose abruptly in the mid 1990s, is continuing to increase, and has now been noted in many countries. By 2030, 25% of American patients diagnosed with rectal cancer will be 49 years or younger. The large majority of EOCRC cases are not found in patients with germline cancer susceptibility mutations (eg, Lynch syndrome) or inflammatory bowel disease. Thus, environmental or lifestyle factors are suspected drivers. Obesity, sedentary lifestyle, diabetes mellitus, smoking, alcohol, or antibiotics affecting the gut microbiome have been proposed. However, these factors, which have been present since the 1950s, have not yet been conclusively linked to the abrupt increase in EOCRC. The sharp increase suggests the introduction of a new risk factor for young people. We hypothesized that the driver may be an off-target effect of a pharmaceutical agent (ie, one requiring regulatory approval before its use in the general population or an off-label use of a previously approved agent) in a genetically susceptible subgroup of young adults. If a pharmaceutical agent is an EOCRC driving factor, regulatory risk mitigation strategies could be used. ObjectiveWe aimed to evaluate the possibility that pharmaceutical agents serve as risk factors for EOCRC. MethodsWe conducted a case-control study. Data including demographics, comorbidities, and complete medication dispensing history were obtained from the electronic medical records database of Maccabi Healthcare Services, a state-mandated health provider covering 26% of the Israeli population. The participants included 941 patients with EOCRC (≤50 years of age) diagnosed during 2001-2019 who were density matched at a ratio of 1:10 with 9410 control patients. Patients with inflammatory bowel disease and those with a known inherited cancer susceptibility syndrome were excluded. An advanced machine learning algorithm based on gradient boosted decision trees coupled with Bayesian model optimization and repeated data sampling was used to sort through the very high-dimensional drug dispensing data to identify specific medication groups that were consistently linked with EOCRC while allowing for synergistic or antagonistic interactions between medications. Odds ratios for the identified medication classes were obtained from a conditional logistic regression model. ResultsOut of more than 800 medication classes, we identified several classes that were consistently associated with EOCRC risk across independently trained models. Interactions between medication groups did not seem to substantially affect the risk. In our analysis, drug groups that were consistently positively associated with EOCRC included beta blockers and valerian (Valeriana officinalis). Antibiotics were not consistently associated with EOCRC risk. ConclusionsOur analysis suggests that the development of EOCRC may be correlated with prior use of specific medications. Additional analyses should be used to validate the results. The mechanism of action inducing EOCRC by candidate pharmaceutical agents will then need to be determined.
- Published
- 2023
- Full Text
- View/download PDF
8. Hepatic disease control in patients with intrahepatic cholangiocarcinoma correlates with overall survival
- Author
-
Kevin C. Soares, Joshua S. Jolissaint, Sarah M. McIntyre, Kenneth P. Seier, Mithat Gönen, Carlie Sigel, Naaz Nasar, Andrea Cercek, James J. Harding, Nancy E. Kemeny, Louise C. Connell, Bas Groot Koerkamp, Vinod P. Balachandran, Michael I. D'Angelica, Jeffrey A. Drebin, T. Peter Kingham, Alice C. Wei, and William R. Jarnagin
- Subjects
bile duct cancer ,biliary neoplasm ,cholangiocarcinoma ,hepatic artery pump ,locoregional therapy ,regional chemotherapy ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Purpose The role of locoregional therapy compared to systemic chemotherapy (SYS) for unresectable intrahepatic cholangiocarcinoma (IHC) remains controversial. The importance of hepatic disease control, either as initial or salvage therapy, is also unclear. We compared overall survival (OS) in patients treated with resection, hepatic arterial infusion pump (HAIP) chemotherapy, or SYS as it relates to hepatic recurrence or progression. We also evaluated recurrence after resection to determine the efficacy of locoregional salvage therapy. Patients and Methods In this single‐institution retrospective analysis, patients with biopsy‐proven IHC treated with either curative‐intent resection, HAIP (with or without SYS), or SYS alone were analyzed. Propensity score matching (PSM) was used to compare patients with liver‐limited, advanced disease treated with HAIP versus SYS. The impact of locoregional salvage therapies in patients with liver‐limited recurrence was analyzed in the resection cohort. Results From 2000 to 2017, 714 patients with IHC were treated, 219 (30.7%) with resectable disease, 316 (44.3%) with locally advanced disease, and 179 (25.1%) with metastatic disease. Resected patients were less likely to recur or progress in the liver (hazard ratio [HR] 0.41, 95% CI 0.34–0.45) versus those that received HAIP or SYS (HR 0.58, 95% CI 0.50–0.65 vs. HR 0.63, 95% CI 0.57–0.69, respectively). In resected patients, 161 (64.4%) recurred, with 65 liver‐only recurrences. Thirty of these patients received subsequent locoregional therapy. On multivariable analysis, locoregional therapy was associated with improved OS after isolated liver recurrence (HR 0.46, 95% CI 0.29–0.75; p = 0.002). In patients with locally advanced unresectable or multifocal liver disease (with or without distant organ metastases), PSM demonstrated improved hepatic progression‐free survival in patients treated with HAIP versus SYS (HR 0.65; 95% CI 0.46–0.91; p = 0.01), which correlated with improved OS (HR 0.59, 95% CI 0.43–0.80; p
- Published
- 2023
- Full Text
- View/download PDF
9. Early-onset Colorectal Cancer Patients Do Not Require Shorter Intervals for Post-surgical Surveillance Colonoscopy
- Author
-
Mendelsohn, Robin B., Hahn, Anne I., Palmaira, Randze Lerie, Saxena, Asha R., Mukthinuthalapati, Pavan Kedar, Schattner, Mark A., Markowitz, Arnold J., Ludwig, Emmy, Shah, Pari, Calo, Delia, Gerdes, Hans, Yaeger, Rona, Stadler, Zsofia, Zauber, Ann G., and Cercek, Andrea
- Published
- 2024
- Full Text
- View/download PDF
10. Oncologic Outcomes of Salvage Abdominoperineal Resection for Anal Squamous Cell Carcinoma Initially Managed with Chemoradiation
- Author
-
Roni Rosen, Felipe F. Quezada-Diaz, Mithat Gönen, Georgios Karagkounis, Maria Widmar, Iris H. Wei, J. Joshua Smith, Garrett M. Nash, Martin R. Weiser, Philip B. Paty, Andrea Cercek, Paul B. Romesser, Francisco Sanchez-Vega, Mohammad Adileh, Diana Roth O’Brien, Carla Hajj, Vonetta M. Williams, Marina Shcherba, Ping Gu, Christopher Crane, Leonard B. Saltz, Julio Garcia Aguilar, and Emmanouil Pappou
- Subjects
anal cancer ,salvage APR ,combined modality treatment ,Medicine - Abstract
Background: Abdominoperineal resection (APR) has been advocated for persistent or recurrent disease after failure of chemoradiation (CRT) for anal squamous cell cancer (SCC). Treatment with salvage APR can potentially achieve a cure. This study aimed to analyze oncological outcomes for salvage APR in a recent time period at a comprehensive cancer center. Methods: A retrospective review of all patients who underwent APR for biopsy-proven persistent or recurrent anal SCC between 1 January 2007 and 31 December 2020 was performed. Patients with stage IV disease at the time of initial diagnosis and patients with missing data were excluded. Univariate analysis was used with a chi-square test for categorical variables, and non-parametric tests were used for continuous variables. Kaplan–Meier survival analysis was performed to evaluate disease-specific (DSS), post-APR local recurrence-free (RFS), and disease-free survival (DFS). Results: A total of 96 patients were included in the analysis: 39 (41%) with persistent disease and 57 (59%) with recurrent SCC after chemoradiation had been completed. The median follow-up was 22 months (IQR 11–47). Forty-nine patients (51%) underwent extended APR and/or pelvic exenteration. Eight (8%) patients developed local recurrence, 30 (31%) developed local and distant recurrences, and 16 (17%) developed distant recurrences alone. The 3-year DSS, post-APR local recurrence-free survival, and disease-free survival were 53.8% (95% CI 43.5–66.5%), 54.5% (95% CI 44.4–66.8%), and 26.8% (95% CI 18.6–38.7%), respectively. In multivariate logistic regression analysis, positive microscopic margin (OR 10.0, 95% CI 2.16–46.12, p = 0.003), positive nodes in the surgical specimen (OR 9.19, 95% CI 1.99–42.52, p = 0.005), and lymphovascular invasion (OR 2.61 95% CI 1.05–6.51, p = 0.04) were associated with recurrence of disease. Gender, indication for APR (recurrent vs. persistent disease), HIV status, extent of surgery, or type of reconstruction did not influence survival outcomes. Twenty patients had targeted tumor-sequencing data available. Nine patients had PIK3CA mutations, seven of whom experienced a recurrence. Conclusions: Salvage APR for anal SCC after failed CRT was associated with poor disease-specific survival and low recurrence-free survival. Anal SCC patients undergoing salvage APR should be counseled that microscopic positive margins, positive lymph nodes, or the presence of lymphovascular invasion in the APR specimen are prognosticators for disease relapse. Our results accentuate the necessity for additional treatment strategies for the ongoing treatment challenge of persistent or recurrent anal SCC after failed CRT.
- Published
- 2024
- Full Text
- View/download PDF
11. Clinical features of young onset colorectal cancer patients from a large cohort at a single cancer center
- Author
-
Park, Leslie, O’Connell, Kelli, Herzog, Keri, Chatila, Walid, Walch, Henry, Palmaira, Randze Lerie D., Cercek, Andrea, Shia, Jinru, Shike, Moshe, Markowitz, Arnold J., Garcia-Aguilar, Julio, Schattner, Mark A., Kantor, Elizabeth D., Du, Mengmeng, and Mendelsohn, Robin B.
- Published
- 2022
- Full Text
- View/download PDF
12. Local Therapy for Oligoprogression or Consolidation in High Mutational Burden Stage 4 Colorectal Cancer Treated With PD-1 or PD-L1 Blockade
- Author
-
Klemen, Nicholas D., Court, Colin M., Fernandes, Maria Clara, Walch, Henry S., Chatila, Walid K., Saadat, Lily V., Maron, Steven, Crane, Chris, Shia, Jinru, Cercek, Andrea, Gönen, Mithat, Schultz, Nikolaus D., Garcia Aguilar, Julio, Jarnagin, William R., and D’Angelica, Michael I.
- Published
- 2022
- Full Text
- View/download PDF
13. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study
- Author
-
Van Cutsem, Eric, Peeters, Marc, Van den Evnde, Marc, André, Thierry, Borg, Christophe, Sarabi, Matthieu, Ghiringhelli, Francois, Chibaudel, Benoist, Siena, Salvatore, Cremolini, Chiara, Zampino, Maria G., Elez, Elena, Keranen, Susana R., Salazar, Ramon, Alfonso, Pilar, Strickler, John H., Cercek, Andrea, Ng, Kimmie, Wu, Christina, Paulson, Andrew S., Hubbard, Joleen M., Coveler, Andrew L., Fountzilas, Christos, Kardosh, Adel, Kasi, Pashtoon M., Lenz, Heinz-Josef, Ciombor, Kristen K., Bajor, David L., Bekaii-Saab, Tanios S., Gbolahan, Olumide, Boland, Patrick, Berg, Daniel, Sanchez, Federico, Goggins, Timothy, Saeed, Anwar, Burris, Howard, Bendell, Johanna, Outlaw, Darryl, Tafur, Isaac, Shergill, Ardaman, Catenacci, Daniel, Gong, Jun, Garrido-Laguna, Ignacio, Finley, Gene, Weinberg, Benjamin, Shields, Anthony, Philip, Philip, Turk, Anita, Nguyen, Anthony, Braiteh, Fadi, Patel, Vijay, Harwin, William, Anderson, Ian, Kundra, Ajay, Chen, Christopher, Ford, James, Kundranda, Madappa, Nguyen, Danny, Ratnam, Suresh, Richards, Donald, Nallapareddy, Sujatha, Beeram, Sridhar, McKenney, Scott, Shao, Spencer, Strickler, John H, Paulson, Andrew S, Hubbard, Joleen M, Coveler, Andrew L, Kasi, Pashtoon M, Ciombor, Kristen K, Bajor, David L, Stecher, Michael, Feng, Wentao, and Bekaii-Saab, Tanios S
- Published
- 2023
- Full Text
- View/download PDF
14. Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer
- Author
-
Chatila, Walid K., Kim, Jin K., Walch, Henry, Marco, Michael R., Chen, Chin-Tung, Wu, Fan, Omer, Dana M., Khalil, Danny N., Ganesh, Karuna, Qu, Xuan, Luthra, Anisha, Choi, Seo-Hyun, Ho, Yu-Jui, Kundra, Ritika, Groves, Katharine I., Chow, Oliver S., Cercek, Andrea, Weiser, Martin R., Widmar, Maria, Wei, Iris H., Pappou, Emmanouil P., Nash, Garrett M., Paty, Philip B., Shi, Qian, Vakiani, Efsevia, Duygu Selcuklu, S., Donoghue, Mark T. A., Solit, David B., Berger, Michael F., Shia, Jinru, Pelossof, Raphael, Romesser, Paul B., Yaeger, Rona, Smith, J. Joshua, Schultz, Nikolaus, Sanchez-Vega, Francisco, and Garcia-Aguilar, Julio
- Published
- 2022
- Full Text
- View/download PDF
15. The Influence of Late Gadolinium Enhancement Cardiac Magnetic Resonance Image Analysis Imprecision on Myocardial Damage Quantification in Patients with Myocarditis: A Pilot Study
- Author
-
Lana Kralj, Andreja Cerne Cercek, Alja Gomišček Novak, and Borut Kirn
- Subjects
myocarditis ,cardiac magnetic resonance ,variability ,full width at half maximum ,thresholding methods ,segmentation ,Technology ,Engineering (General). Civil engineering (General) ,TA1-2040 ,Biology (General) ,QH301-705.5 ,Physics ,QC1-999 ,Chemistry ,QD1-999 - Abstract
Background: Myocardial damage in myocarditis is assessed through late gadolinium enhancement (LGE) cardiac magnetic resonance (CMR). Variability in quantifying myocarditis extent results from imprecise image segmentation and inconclusive data on quantification method selection. To improve analysis precision, segmentation steps are systematically ranked based on their inherent risks of error. Additionally, data on two distinct quantification methods are presented. Methods: Using newly developed software, four experts analyzed five LGE-CMR left ventricular (LV) short-axis (SAx) images of myocarditis patients in three sessions. Regions of interest (ROIs) (myocardial (ROImyoc), reference (ROIref), and exclusion region (ROIexcl)) were identified and used to calculate LGE extent with 3σ (intensity above three standard deviations (σ) in reference) and the full width at half maximum (FWHM) method (intensity above 50% of maximum signal in reference). The reference LGE extent was calculated and the influence of the ROIs on LGE extent variability was determined. Interobserver and intraobserver variability were evaluated as 1-intraclass correlation coefficient (ICC). Results: LGE extent variability was 6.2 ± 0.6% for 3σ and 4.0 ± 0.6% for FWHM. The contributions of ROImyoc, ROIref, and ROIexcl were 1.5 ± 0.2%, 2.7 ± 0.4%, and 2 ± 0.3%, respectively, for 3σ, and 1.1 ± 0.1%, 1.6 ± 0.4%, and 1.3 ± 0.3%, respectively, for FWHM. LGE extent was lower in FWHM. Interobserver variability was 0.56 for 3σ and 0.43 for FWHM. The intraobserver variability was higher for the 3σ method in all four observers. Conclusion: ROIref selection contributed most to LGE extent variability. FWHM yielded lower LGE extent and lower inter- and intraobserver variability. Due to low statistical significance, the findings are only partially confirmed.
- Published
- 2023
- Full Text
- View/download PDF
16. Delphi Initiative for Early-Onset Colorectal Cancer (DIRECt) International Management Guidelines
- Author
-
Cavestro, Giulia Martina, Mannucci, Alessandro, Balaguer, Francesc, Hampel, Heather, Kupfer, Sonia S., Repici, Alessandro, Sartore-Bianchi, Andrea, Seppälä, Toni T., Valentini, Vincenzo, Boland, Clement Richard, Brand, Randall E., Buffart, Tineke E., Burke, Carol A., Caccialanza, Riccardo, Cannizzaro, Renato, Cascinu, Stefano, Cercek, Andrea, Crosbie, Emma J., Danese, Silvio, Dekker, Evelien, Daca-Alvarez, Maria, Deni, Francesco, Dominguez-Valentin, Mev, Eng, Cathy, Goel, Ajay, Guillem, Josè G., Houwen, Britt B.S.L., Kahi, Charles, Kalady, Matthew F., Kastrinos, Fay, Kühn, Florian, Laghi, Luigi, Latchford, Andrew, Liska, David, Lynch, Patrick, Malesci, Alberto, Mauri, Gianluca, Meldolesi, Elisa, Møller, Pål, Monahan, Kevin J., Möslein, Gabriela, Murphy, Caitlin C., Nass, Karlijn, Ng, Kimmie, Oliani, Cristina, Papaleo, Enrico, Patel, Swati G., Puzzono, Marta, Remo, Andrea, Ricciardiello, Luigi, Ripamonti, Carla Ida, Siena, Salvatore, Singh, Satish K., Stadler, Zsofia K., Stanich, Peter P., Syngal, Sapna, Turi, Stefano, Urso, Emanuele Damiano, Valle, Laura, Vanni, Valeria Stella, Vilar, Eduardo, Vitellaro, Marco, You, Yi-Qian Nancy, Yurgelun, Matthew B., Zuppardo, Raffaella Alessia, and Stoffel, Elena M.
- Published
- 2023
- Full Text
- View/download PDF
17. Impact of chronic obstructive pulmonary disease on short-term outcome in patients with ST-elevation myocardial infarction during COVID-19 pandemic: insights from the international multicenter ISACS-STEMI registry
- Author
-
Giuseppe De Luca, Matteo Nardin, Magdy Algowhary, Berat Uguz, Dinaldo C. Oliveira, Vladimir Ganyukov, Zan Zimbakov, Miha Cercek, Lisette Okkels Jensen, Poay Huan Loh, Lucian Calmac, Gerard Roura Ferrer, Alexandre Quadros, Marek Milewski, Fortunato Scotto di Uccio, Clemens von Birgelen, Francesco Versaci, Jurrien Ten Berg, Gianni Casella, Aaron Wong Sung Lung, Petr Kala, José Luis Díez Gil, Xavier Carrillo, Maurits Dirksen, Victor M. Becerra-Munoz, Michael Kang-yin Lee, Dafsah Arifa Juzar, Rodrigo de Moura Joaquim, Roberto Paladino, Davor Milicic, Periklis Davlouros, Nikola Bakraceski, Filippo Zilio, Luca Donazzan, Adriaan Kraaijeveld, Gennaro Galasso, Arpad Lux, Lucia Marinucci, Vincenzo Guiducci, Maurizio Menichelli, Alessandra Scoccia, Aylin Hatice Yamac, Kadir Ugur Mert, Xacobe Flores Rios, Tomas Kovarnik, Michal Kidawa, Josè Moreu, Vincent Flavien, Enrico Fabris, Iñigo Lozano Martínez-Luengas, Marco Boccalatte, Francisco Bosa Ojeda, Carlos Arellano-Serrano, Gianluca Caiazzo, Giuseppe Cirrincione, Hsien-Li Kao, Juan Sanchis Forés, Luigi Vignali, Helder Pereira, Stephane Manzo, Santiago Ordoñez, Alev Arat Özkan, Bruno Scheller, Heidi Lehtola, Rui Teles, Christos Mantis, Ylitalo Antti, João A. Brum Silveira, Rodrigo Zoni, Ivan Bessonov, Stefano Savonitto, George Kochiadakis, Dimitrios Alexopoulos, Carlos E. Uribe, John Kanakakis, Benjamin Faurie, Gabriele Gabrielli, Alejandro Gutierrez Barrios, Juan Pablo Bachini, Alex Rocha, Frankie Chor-Cheung Tam, Alfredo Rodriguez, Antonia Anna Lukito, Veauthyelau Saint-Joy, Gustavo Pessah, Andrea Tuccillo, Giuliana Cortese, Guido Parodi, Mohamed Abed Bouraghda, Elvin Kedhi, Pablo Lamelas, Harry Suryapranata, and Monica Verdoia
- Subjects
STEMI ,COPD ,Mortality ,Diseases of the respiratory system ,RC705-779 - Abstract
Abstract Background Chronic obstructive pulmonary disease (COPD) is projected to become the third cause of mortality worldwide. COPD shares several pathophysiological mechanisms with cardiovascular disease, especially atherosclerosis. However, no definite answers are available on the prognostic role of COPD in the setting of ST elevation myocardial infarction (STEMI), especially during COVID-19 pandemic, among patients undergoing primary angioplasty, that is therefore the aim of the current study. Methods In the ISACS-STEMI COVID-19 registry we included retrospectively patients with STEMI treated with primary percutaneous coronary intervention (PCI) between March and June of 2019 and 2020 from 109 high-volume primary PCI centers in 4 continents. Results A total of 15,686 patients were included in this analysis. Of them, 810 (5.2%) subjects had a COPD diagnosis. They were more often elderly and with a more pronounced cardiovascular risk profile. No preminent procedural dissimilarities were noticed except for a lower proportion of dual antiplatelet therapy at discharge among COPD patients (98.9% vs. 98.1%, P = 0.038). With regards to short-term fatal outcomes, both in-hospital and 30-days mortality occurred more frequently among COPD patients, similarly in pre-COVID-19 and COVID-19 era. However, after adjustment for main baseline differences, COPD did not result as independent predictor for in-hospital death (adjusted OR [95% CI] = 0.913[0.658–1.266], P = 0.585) nor for 30-days mortality (adjusted OR [95% CI] = 0.850 [0.620–1.164], P = 0.310). No significant differences were detected in terms of SARS-CoV-2 positivity between the two groups. Conclusion This is one of the largest studies investigating characteristics and outcome of COPD patients with STEMI undergoing primary angioplasty, especially during COVID pandemic. COPD was associated with significantly higher rates of in-hospital and 30-days mortality. However, this association disappeared after adjustment for baseline characteristics. Furthermore, COPD did not significantly affect SARS-CoV-2 positivity. Trial registration number: NCT 04412655 (2nd June 2020).
- Published
- 2022
- Full Text
- View/download PDF
18. Considerations and barriers to starting a new HAI pump program: an international survey of the HAI Consortium Research Network
- Author
-
Cavnar, Michael, Ghalambor, Tara, Lidsky, Michael E., Dominguez-Rosado, Ismael, Cho, May, Karanicolas, Paul, Merkow, Ryan, Mayo, Skye C., Rocha, Flavio G., Fields, Ryan C., Koerkamp, Bas G., Yopp, Adam, Petrowsky, Hendrik, Cercek, Andrea, Kemeny, Nancy, Kingham, Peter, Jarnagin, William, Allen, Peter, D'Angelica, Michael, and Gholami, Sepideh
- Published
- 2022
- Full Text
- View/download PDF
19. Impaired tolerance to the autoantigen LL-37 in acute coronary syndrome
- Author
-
Fernando Chernomordik, Bojan Cercek, Jianchang Zhou, Xiaoning Zhao, Nicole Wai Man Lio, Kuang-Yuh Chyu, Prediman K. Shah, and Paul C. Dimayuga
- Subjects
acute coronary syndrome ,LL-37 ,T cells ,immune checkpoint ,self-antigen ,platelets ,Immunologic diseases. Allergy ,RC581-607 - Abstract
BackgroundLL-37 is the only member of the cathelicidin family of antimicrobial peptides in humans and is an autoantigen in several autoimmune diseases and in acute coronary syndrome (ACS). In this report, we profiled the specific T cell response to the autoimmune self-antigen LL-37 and investigated the factors modulating the response in peripheral blood mononuclear cells (PBMCs) of healthy subjects and ACS patients.Methods and resultsThe activation induced marker (AIM) assay demonstrated differential T cell profiles characterized by the persistence of CD134 and CD137, markers that impair tolerance and promote immune effector and memory response, in ACS compared to Controls. Specifically, CD8+CD69+CD137+ T cells were significantly increased by LL-37 stimulation in ACS PBMCs. T effector cell response to LL-37 were either HLA dependent or independent as determined by blocking with monoclonal antibody to either Class-I HLA or Class-II HLA. Blocking of immune checkpoints PD-1 and CTLA-4 demonstrated the control of self-reactive T cell response to LL-37 was modulated predominantly by CTLA-4. Platelets from healthy controls down-modulated CD8+CD69+CD137+ T cell response to LL-37 in autologous PBMCs. CD8+CD69+CD137+ T cell AIM profile negatively correlated with platelet count in ACS patients.ConclusionsOur report demonstrates that the immune response to the autoantigen LL-37 in ACS patients is characterized specifically by CD8+CD69+CD137+ T cell AIM profile with persistent T cell activation and the generation of immunologic memory. The results provide potentially novel insight into mechanistic pathways of antigen-specific immune signaling in ACS.
- Published
- 2023
- Full Text
- View/download PDF
20. Impact of chronic obstructive pulmonary disease on short-term outcome in patients with ST-elevation myocardial infarction during COVID-19 pandemic: insights from the international multicenter ISACS-STEMI registry
- Author
-
De Luca, Giuseppe, Nardin, Matteo, Algowhary, Magdy, Uguz, Berat, Oliveira, Dinaldo C., Ganyukov, Vladimir, Zimbakov, Zan, Cercek, Miha, Okkels Jensen, Lisette, Loh, Poay Huan, Calmac, Lucian, Roura Ferrer, Gerard, Quadros, Alexandre, Milewski, Marek, Scotto di Uccio, Fortunato, von Birgelen, Clemens, Versaci, Francesco, Ten Berg, Jurrien, Casella, Gianni, Wong Sung Lung, Aaron, Kala, Petr, Díez Gil, José Luis, Carrillo, Xavier, Dirksen, Maurits, Becerra-Munoz, Victor M., Lee, Michael Kang-yin, Arifa Juzar, Dafsah, de Moura Joaquim, Rodrigo, Paladino, Roberto, Milicic, Davor, Davlouros, Periklis, Bakraceski, Nikola, Zilio, Filippo, Donazzan, Luca, Kraaijeveld, Adriaan, Galasso, Gennaro, Lux, Arpad, Marinucci, Lucia, Guiducci, Vincenzo, Menichelli, Maurizio, Scoccia, Alessandra, Yamac, Aylin Hatice, Ugur Mert, Kadir, Flores Rios, Xacobe, Kovarnik, Tomas, Kidawa, Michal, Moreu, Josè, Flavien, Vincent, Fabris, Enrico, Martínez-Luengas, Iñigo Lozano, Boccalatte, Marco, Bosa Ojeda, Francisco, Arellano-Serrano, Carlos, Caiazzo, Gianluca, Cirrincione, Giuseppe, Kao, Hsien-Li, Sanchis Forés, Juan, Vignali, Luigi, Pereira, Helder, Manzo, Stephane, Ordoñez, Santiago, Özkan, Alev Arat, Scheller, Bruno, Lehtola, Heidi, Teles, Rui, Mantis, Christos, Antti, Ylitalo, Brum Silveira, João A., Zoni, Rodrigo, Bessonov, Ivan, Savonitto, Stefano, Kochiadakis, George, Alexopoulos, Dimitrios, Uribe, Carlos E., Kanakakis, John, Faurie, Benjamin, Gabrielli, Gabriele, Gutierrez Barrios, Alejandro, Bachini, Juan Pablo, Rocha, Alex, Tam, Frankie Chor-Cheung, Rodriguez, Alfredo, Lukito, Antonia Anna, Saint-Joy, Veauthyelau, Pessah, Gustavo, Tuccillo, Andrea, Cortese, Giuliana, Parodi, Guido, Bouraghda, Mohamed Abed, Kedhi, Elvin, Lamelas, Pablo, Suryapranata, Harry, and Verdoia, Monica
- Published
- 2022
- Full Text
- View/download PDF
21. MRI radiomics features of mesorectal fat can predict response to neoadjuvant chemoradiation therapy and tumor recurrence in patients with locally advanced rectal cancer
- Author
-
Jayaprakasam, Vetri Sudar, Paroder, Viktoriya, Gibbs, Peter, Bajwa, Raazi, Gangai, Natalie, Sosa, Ramon E., Petkovska, Iva, Golia Pernicka, Jennifer S., Fuqua, III, James Louis, Bates, David D. B., Weiser, Martin R., Cercek, Andrea, and Gollub, Marc J.
- Published
- 2022
- Full Text
- View/download PDF
22. Predicting 10-year survival after resection of colorectal liver metastases; an international study including biomarkers and perioperative treatment
- Author
-
Buisman, Florian E., Giardiello, Daniele, Kemeny, Nancy E., Steyerberg, Ewout W., Höppener, Diederik J., Galjart, Boris, Nierop, Pieter M.H., Balachandran, Vinod P., Cercek, Andrea, Drebin, Jeffrey A., Gönen, Mithat, Jarnagin, William R., Kingham, T.P., Vermeulen, Peter B., Wei, Alice C., Grünhagen, Dirk J., Verhoef, Cornelis, D'Angelica, Micheal I., and Koerkamp, Bas Groot
- Published
- 2022
- Full Text
- View/download PDF
23. Simplified Graded Infusion Strategy for Mitigation of Oxaliplatin Hypersensitivity
- Author
-
Alonso Martinez, Salvador, Segal, Neil H., Cercek, Andrea, Yaeger, Rona, Stadler, Zsofia, Kemeny, Nancy E., Nusrat, Maliha, Shahrokni, Armin, Connell, Louise, and Saltz, Leonard B.
- Published
- 2022
- Full Text
- View/download PDF
24. Type of recurrence is associated with disease-free survival after salvage surgery for locally recurrent rectal cancer
- Author
-
Jimenez-Rodriguez, Rosa M., Yuval, Jonathan B., Sauve, Charles-Etienne Gabriel, Wasserman, Isaac, Aggarwal, Piyush, Romesser, Paul B., Crane, Christopher H., Yaeger, Rona, Cercek, Andrea, Guillem, Jose G., Weiser, Martin R., Wei, Iris H., Widmar, Maria, Nash, Garrett M., Pappou, Emmanouil P., Garcia-Aguilar, Julio, Gollub, Marc J., Paty, Philip B., and Smith, J. Joshua
- Published
- 2021
- Full Text
- View/download PDF
25. Extrahepatic Cholangiocarcinoma: Genomic Variables Associated With Anatomic Location and Outcome.
- Author
-
Preston, William A., Drill, Esther, Boerner, Thomas, Gelfer, Rebecca, Harding, James J., O'Reilly, Eileen M., Cercek, Andrea, Abou-Alfa, Ghassan, Park, Wungki, Balachandran, Vinod P., Drebin, Jeffrey, Soares, Kevin C., Wei, Alice, Kingham, T. Peter, D'Angelica, Michael I., and Jarnagin, William R.
- Subjects
CHOLANGIOCARCINOMA ,NUCLEOTIDE sequencing ,SURVIVAL rate ,DIAGNOSIS - Abstract
PURPOSE: This study aimed to define genomic differences between perihilar cholangiocarcinoma (PCA) and distal cholangiocarcinoma (DCA) and identify genomic determinants of survival. MATERIALS AND METHODS: Consecutive patients with ECA with tissue for targeted next-generation sequencing were analyzed, stratified by anatomic site (PCA/DCA), disease extent, and treatment. Associations between genomic alterations, clinicopathologic features, and outcomes were analyzed using Cox proportional hazards regression to compare survival. RESULTS: In total, 224 patients diagnosed between 2004 and 2022 (n = 127 PCA; n = 97 DCA) met inclusion criteria. The median survival was 29 months (43 after resection and 17 from diagnosis for unresectable disease). Compared with PCA, DCA was enriched in TP53alt (alterations; 69% v 33%; Q < 0.01), epigenetic pathway alterations (45% v 29%; Q = 0.041), and had more total altered pathways (median 3 v 2; Q < 0.01). KRASalt frequency was similar between PCA (36%) and DCA (37%); however, DCA was enriched in KRAS G12D (19% v 9%; P =.002). No other clinicopathologic or genomic variables distinguished subtypes. In resected patients, no genomic alterations were associated with outcome. However, in unresectable patients, CDKN2Aalt (hazard ratio [HR], 2.59 [1.48 to 4.52]) and APCalt (HR, 5.11 [1.96 to 13.3]) were associated with reduced survival. For the entire cohort, irresectability (HR, 3.13 [2.25 to 4.36]), CDKN2Aalt (HR, 1.80 [1.80 to 2.68]), and APCalt (HR, 2.00 [1.04 to 3.87]) were associated with poor survival. CONCLUSION: CDKN2Aalt and APCalt were associated with poor survival in ECA, primarily in advanced disease. As PCA and DCA were genetically similar, coanalysis of PCA and DCA in future genomic studies is reasonable. Genomic alteration patterns are similar between perihilar and distal cholangiocarcinoma. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. Penile-scrotal erythrodysesthesia among rectal cancer patients receiving fluoropyrimidine-based chemoradiation: a case report series.
- Author
-
Adames, Angela, O'Brien, Diana Roth, Kelly, Alison R., Saltz, Leonard B., Garcia-Aguilar, Julio, Zinovoy, Melissa, Williams, Vonetta, Wu, Abraham, Reyngold, Marsha, Hajj, Carla, Crane, Christopher, Cercek, Andrea, Smith, J. Joshua, Markova, Alina, Cuaron, John, McCann, Patrick, and Romesser, Paul B.
- Subjects
CHEMORADIOTHERAPY ,CANCER patients ,HAND-foot syndrome ,PENILE cancer ,RECTAL cancer ,CANCER treatment ,RADIOTHERAPY - Abstract
Background: Palmar-plantar erythrodysesthesia (PPE) is a slowly developing cutaneous reaction commonly experienced by patients treated with fluoropyrimidines. While erythrodysesthesia normally presents in a palmar-plantar distribution, it can also present with genital involvement, but this presentation is likely underreported and incorrectly attributed to an acute reaction from radiation therapy. This article aims to define erythrodysesthesia of the penis and scrotum as a rare but significant side effect of capecitabine. Case presentation: We identified five cases of moderate to severe penis and scrotal erythrodysesthesia over a 2-year period at a large tertiary cancer center, representing an estimated incidence of 3.6% among male patients with rectal cancer who were treated with fluoropyrimidine-based chemoradiation within our institution. Conclusions: Improved understanding of erythrodysesthesia involving the penis and scrotum can facilitate early identification and treatment of symptoms, and possibly prevent the discontinuation or delay of cancer treatment in patients treated with capecitabine and similar drugs. These clinical advances would improve and prolong patient quality of life during cancer treatment and prevent complications that result in hospitalization. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
27. A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS‐102 in irinotecan‐refractory metastatic colorectal cancer patients.
- Author
-
Lee, Valerie, Parkinson, Rose, Zahurak, Marianna, Cope, Leslie, Cercek, Andrea, Verheul, Henk, Gootjes, Elske, Lenz, Heinz Josef, Iqbal, Syma, Jones, Peter, Baylin, Stephen, Rami, Vandna, Ahuja, Nita, El Khoueiry, Anthony, and Azad, Nilofer S.
- Subjects
IRINOTECAN ,COLORECTAL cancer ,METASTASIS ,PROGRESSION-free survival ,REGORAFENIB - Abstract
DNA methyltransferase inhibitors (DNMTi) have demonstrated benefit in reversing resistance to systemic therapies for several cancer types. In a phase II trial of guadecitabine and irinotecan compared to regorafenib or TAS‐102 in pts with advanced mCRC refractory to irinotecan. Patients with mCRC refractory to irinotecan were randomized 2:1 to guadecitabine and irinotecan (Arm A) vs standard of care regorafenib or TAS‐102 (Arm B) on a 28‐day cycle. Between January 15, 2016 and October 24, 2018, 104 pts were randomized at four international sites, with 96 pts undergoing treatment, 62 in Arm A and 34 in Arm B. Median overall survival was 7.15 months for Arm A and 7.66 months for Arm B (HR 0.93, 95% CI: 0.58–1.47, P =.75). The Kaplan–Meier rates of progression free survival at 4 months were 32% in Arm A and 26% in Arm B. Common ≥Grade 3 treatment related adverse events in Arm A were neutropenia (42%), anemia (18%), diarrhea (11%), compared to Arm B pts with neutropenia (12%), anemia (12%). Guadecitabine and irinotecan had similar OS compared to standard of care TAS‐102 or regorafenib, with evidence of target modulation. Clinical trial information: NCT01896856. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
28. Immune Checkpoint Inhibitor Therapy in Locally Advanced MSI GI Malignancies.
- Author
-
Harrold, Emily C., Keane, Fergus, and Cercek, Andrea
- Published
- 2024
29. Renin-angiotensin system inhibitors and mortality among diabetic patients with STEMI undergoing mechanical reperfusion during the COVID-19 pandemic
- Author
-
De Luca, Giuseppe, Nardin, Matteo, Algowhary, Magdy, Uguz, Berat, Oliveira, Dinaldo C, Ganyukov, Vladimir, Zimbakov, Zan, Cercek, Miha, Jensen, Lisette Okkels, LOH, Poay Huan, Calmac, Lucian, Roura Ferrer, Gerard, Quadros, Alexandre, Milewski, Marek, Scotto di Uccio, Fortunato, von Birgelen, Clemens, Versaci, Francesco, Ten Berg, Jurrien, Casella, Gianni, Lung, Aaron Wong Sung, Kala, Petr, Díez Gil, José Luis, Carrillo, Xavier, Dirksen, Maurits, Becerra-Munoz, Victor M., Lee, Michael Kang-yin, Juzar, Dafsah Arifa, de Moura Joaquim, Rodrigo, Paladino, Roberto, Milicic, Davor, Davlouros, Periklis, Bakraceski, Nikola, Zilio, Filippo, Donazzan, Luca, Kraaijeveld, Adriaan, Galasso, Gennaro, Lux, Arpad, Marinucci, Lucia, Guiducci, Vincenzo, Menichelli, Maurizio, Scoccia, Alessandra, Yamac, Aylin Hatice, Mert, Kadir Ugur, Flores Rios, Xacobe, Kovarnik, Tomas, Kidawa, Michal, Moreu, Josè, Flavien, Vincent, Fabris, Enrico, Martínez-Luengas, Iñigo Lozano, Boccalatte, Marco, Bosa Ojeda, Francisco, Arellano-Serrano, Carlos, Caiazzo, Gianluca, Cirrincione, Giuseppe, Kao, Hsien-Li, Sanchis Forés, Juan, Vignali, Luigi, Pereira, Helder, Manzo, Stephane, Ordoñez, Santiago, Arat Özkan, Alev, Scheller, Bruno, Lehtola, Heidi, Teles, Rui, Mantis, Christos, Antti, Ylitalo, Brum Silveira, João António, Zoni, Rodrigo, Bessonov, Ivan, Savonitto, Stefano, Kochiadakis, George, Alexopulos, Dimitrios, Uribe, Carlos E, Kanakakis, John, Faurie, Benjamin, Gabrielli, Gabriele, Gutierrez Barrios, Alejandro, Bachini, Juan Pablo, Rocha, Alex, Tam, Frankie Chor-Cheung, Rodriguez, Alfredo, Lukito, Antonia Anna, Saint-Joy, Veauthyelau, Pessah, Gustavo, Tuccillo, Andrea, Cortese, Giuliana, Parodi, Guido, Bouraghda, Mohammed Abed, Kedhi, Elvin, Lamelas, Pablo, Suryapranata, Harry, and Verdoia, Monica
- Published
- 2021
- Full Text
- View/download PDF
30. Impact of SARS-CoV-2 positivity on clinical outcome among STEMI patients undergoing mechanical reperfusion: Insights from the ISACS STEMI COVID 19 registry
- Author
-
De Luca, Giuseppe, Debel, Niels, Cercek, Miha, Jensen, Lisette Okkels, Vavlukis, Marija, Calmac, Lucian, Johnson, Tom, Ferrer, Gerard Rourai, Ganyukov, Vladimir, Wojakowski, Wojtek, Kinnaird, Tim, von Birgelen, Clemens, Cottin, Yves, IJsselmuiden, Alexander, Tuccillo, Bernardo, Versaci, Francesco, Royaards, Kees-Jan, Berg, Jurrien ten, Laine, Mika, Dirksen, Maurits, Siviglia, Massimo, Casella, Gianni, Kala, Petr, Díez Gil, José Luis, Banning, Adrian, Becerra, Victor, De Simone, Ciro, Santucci, Andrea, Carrillo, Xavier, Scoccia, Alessandra, Amoroso, Giovanni, van't Hof, Arnoud WJ., Kovarnik, Tomas, Tsigkas, Grigorios, Mehilli, Julinda, Gabrielli, Gabriele, Rios, Xacobe Flores, Bakraceski, Nikola, Levesque, Sébastien, Cirrincione, Giuseppe, Guiducci, Vincenzo, Kidawa, Michał, Spedicato, Leonardo, Marinucci, Lucia, Ludman, Peter, Zilio, Filippo, Galasso, Gennaro, Fabris, Enrico, Menichelli, Maurizio, Garcia-Touchard, Arturo, Manzo, Stephane, Caiazzo, Gianluca, Moreu, Jose, Forés, Juan Sanchis, Donazzan, Luca, Vignali, Luigi, Teles, Rui, Benit, Edouard, Agostoni, Pierfrancesco, Ojeda, Francisco Bosa, Lehtola, Heidi, Camacho-Freiere, Santiago, Kraaijeveld, Adriaan, Antti, Ylitalo, Boccalatte, Marco, Deharo, Pierre, Martínez-Luengas, Iñigo Lozano, Scheller, Bruno, Varytimiadi, Efthymia, Moreno, Raul, Uccello, Giuseppe, Faurie, Benjamin, Gutierrez Barrios, Alejandro, Milewski, Marek, Bruwiere, Ewout, Smits, Pieter, Wilbert, Bor, Di Uccio, Fortunato Scotto, Parodi, Guido, Kedhi, Elvin, and Verdoia, Monica
- Published
- 2021
- Full Text
- View/download PDF
31. Impact of renin-angiotensin system inhibitors on mortality during the COVID Pandemic among STEMI patients undergoing mechanical reperfusion: Insight from an international STEMI registry
- Author
-
De Luca, Giuseppe, Cercek, Miha, Okkels Jensen, Lisette, Bushljetikj, Oliver, Calmac, Lucian, Johnson, Tom, Gracida Blancas, Montserrat, Ganyukov, Vladimir, Wojakowski, Wojtek, von Birgelen, Clemens, IJsselmuiden, Alexander, Tuccillo, Bernardo, Versaci, Francesco, Ten Berg, Jurrien, Laine, Mika, Berkout, Tim, Casella, Gianni, Kala, Petr, López Ledesma, Bernabé, Becerra, Victor, Padalino, Roberto, Santucci, Andrea, Carrillo, Xavier, Scoccia, Alessandra, Amoroso, Giovanni, Lux, Arpad, Kovarnik, Tomas, Davlouros, Periklis, Gabrielli, Gabriele, Flores Rios, Xacobe, Bakraceski, Nikola, Levesque, Sébastien, Guiducci, Vincenzo, Kidawa, Michał, Marinucci, Lucia, Zilio, Filippo, Galasso, Gennaro, Fabris, Enrico, Menichelli, Maurizio, Manzo, Stephane, Caiazzo, Gianluca, Moreu, Jose, Sanchis Forés, Juan, Donazzan, Luca, Vignali, Luigi, Teles, Rui, Agostoni, Pierfrancesco, Bosa Ojeda, Francisco, Lehtola, Heidi, Camacho-Freiere, Santiago, Kraaijeveld, Adriaan, Antti, Ylitalo, Visconti, Gabriella, Lozano Martínez-Luengas, Iñigo, Scheller, Bruno, Alexopulos, Dimitrios, Moreno, Raul, Kedhi, Elvin, Uccello, Giuseppe, Faurie, Benjamin, Gutierrez Barrios, Alejandro, Scotto Di Uccio, Fortunato, Wilbert, Bor, Cortese, Giuliana, Dirksen, Maurits T., Parodi, Guido, and Verdoia, Monica
- Published
- 2021
- Full Text
- View/download PDF
32. Factors Associated With Local Tumor Control and Complications After Thermal Ablation of Colorectal Cancer Liver Metastases: A 15-year Retrospective Cohort Study
- Author
-
Kurilova, Ieva, Bendet, Achiude, Petre, Elena N., Boas, Franz E., Kaye, Elena, Gonen, Mithat, Covey, Anne, Brody, Lynn A., Brown, Karen T., Kemeny, Nancy E., Yarmohammadi, Hooman, Ziv, Etay, D’Angelica, Michael I., Kingham, T. Peter, Cercek, Andrea, Solomon, Steven B., Beets-Tan, Regina G.H., and Sofocleous, Constantinos T.
- Published
- 2021
- Full Text
- View/download PDF
33. Impact of Primary Tumor Laterality on Adjuvant Hepatic Artery Infusion Pump Chemotherapy in Resected Colon Cancer Liver Metastases: Analysis of 487 Patients
- Author
-
Gholami, Sepideh, Stewart, Susan, Kemeny, Nancy, Gönen, Mithat, Groot Koerkamp, Bas, Cercek, Andrea, Kingham, Peter, Balachandran, Vinod, Allen, Peter, DeMatteo, Ronald, Wei, Alice, Connell, Louise, Drebin, Jeffrey, Jarnagin, William, and D’Angelica, Michael
- Published
- 2021
- Full Text
- View/download PDF
34. Radiation segmentectomy of hepatic metastases with Y-90 glass microspheres
- Author
-
Kurilova, I., Bendet, A., Fung, E. K., Petre, E. N., Humm, J. L., Boas, F. E., Crane, C. H., Kemeny, N., Kingham, T. P., Cercek, A., D’Angelica, M. I., Beets-Tan, R. G. H., and Sofocleous, C. T.
- Published
- 2021
- Full Text
- View/download PDF
35. Immunization using ApoB-100 peptide–linked nanoparticles reduces atherosclerosis
- Author
-
Kuang-Yuh Chyu, Xiaoning Zhao, Jianchang Zhou, Paul C. Dimayuga, Nicole W.M. Lio, Bojan Cercek, Noah T. Trac, Eun Ji Chung, and Prediman K. Shah
- Subjects
Cardiology ,Vaccines ,Medicine - Abstract
Active immunization with the apolipoprotein B-100 (ApoB-100) peptide P210 reduces experimental atherosclerosis. To advance this immunization strategy to future clinical testing, we explored the possibility of delivering P210 as an antigen using nanoparticles, given this approach has been used clinically. We first characterized the responses of T cells to P210 using PBMCs from patients with atherosclerotic cardiovascular disease (ASCVD). We then investigated the use of P210 in self-assembling peptide amphiphile micelles (P210-PAMs) as a vaccine formulation to reduce atherosclerosis in B6.129P2-Apoetm1Unc/J (ApoE–/–) mice and P210’s potential mechanisms of action. We also generated and characterized a humanized mouse model with chimeric HLA-A*02:01/Kb in ApoE–/– background to test the efficacy of P210-PAM immunization as a bridge to future clinical testing. P210 provoked T cell activation and memory response in PBMCs of patients with ASCVD. Dendritic cell uptake of P210-PAM and its costaining with MHC-I molecules supported its use as a vaccine formulation. In ApoE–/– mice, immunization with P210-PAMs dampened P210-specific CD4+ T cell proliferative response and CD8+ T cell cytolytic response, modulated macrophage phenotype, and significantly reduced aortic atherosclerosis. Potential clinical relevance of P210-PAM immunization was demonstrated by reduced atherosclerosis in the humanized ApoE–/– mouse model. Our data support experimental and translational use of P210-PAM as a potential vaccine candidate against human ASCVD.
- Published
- 2022
- Full Text
- View/download PDF
36. Early liver metastases after “failure” of adjuvant chemotherapy for stage III colorectal cancer: is there a role for additional adjuvant therapy?
- Author
-
Boerner, Thomas, Zambirinis, Constantinos, Gagnière, Johan, Chou, Joanne F., Gonen, Mithat, Kemeny, Nancy E., Cercek, Andrea, Connell, Louise C., Kingham, Thomas P., Allen, Peter J., Balachandran, Vinod P., Drebin, Jeffrey, Jarnagin, William R., and D'Angelica, Michael I.
- Published
- 2021
- Full Text
- View/download PDF
37. Age-Related Effects of COVID-19 Pandemic on Mechanical Reperfusion and 30-Day Mortality for STEMI: Results of the ISACS-STEMI COVID-19 Registry
- Author
-
Giuseppe De Luca, Magdy Algowhary, Berat Uguz, Dinaldo C. Oliveira, Vladimir Ganyukov, Oliver Busljetik, Miha Cercek, Lisette Okkels Jensen, Poay Huan Loh, Lucian Calmac, Gerard Roura i Ferrer, Alexandre Quadros, Marek Milewski, Fortunato Scotto D’Uccio, Clemens von Birgelen, Francesco Versaci, Jurrien Ten Berg, Gianni Casella, Aaron Wong Sung Lung, Petr Kala, José Luis Díez Gil, Xavier Carrillo, Maurits Dirksen, Victor Becerra Munoz, Michael Kang-yin Lee, Dafsah Arifa Juzar, Rodrigo de Moura Joaquim, Roberto Paladino, Davor Milicic, Periklis Davlouros, Nikola Bakraceski, Filippo Zilio, Luca Donazzan, Adriaan Kraaijeveld, Gennaro Galasso, Lux Arpad, Lucia Marinucci, Vincenzo Guiducci, Maurizio Menichelli, Alessandra Scoccia, Aylin Hatice Yamac, Kadir Ugur Mert, Xacobe Flores Rios, Tomas Kovarnik, Michal Kidawa, Josè Moreu, Vincent Flavien, Enrico Fabris, Iñigo Lozano Martínez-Luengas, Marco Boccalatte, Francisco Bosa Ojeda, Carlos Arellano-Serrano, Gianluca Caiazzo, Giuseppe Cirrincione, Hsien-Li Kao, Juan Sanchis Forés, Luigi Vignali, Helder Pereira, Stephane Manzo-Silberman, Santiago Ordoñez, Alev Arat Özkan, Bruno Scheller, Heidi Lehitola, Rui Teles, Christos Mantis, Ylitalo Antti, João António Brum Silveira, Cesar Rodrigo Zoni, Ivan Bessonov, Giuseppe Uccello, George Kochiadakis, Dimitrios Alexopulos, Carlos E. Uribe, John Kanakakis, Benjamin Faurie, Gabriele Gabrielli, Alejandro Gutierrez Barrios, Juan Pablo Bachini, Alex Rocha, Frankie C. C. Tam, Alfredo Rodriguez, Antonia Anna Lukito, Veauthyelau Saint-Joy, Gustavo Pessah, Andrea Tuccillo, Alfonso Ielasi, Giuliana Cortese, Guido Parodi, Mohammed Abed Burgadha, Elvin Kedhi, Pablo Lamelas, Harry Suryapranata, Matteo Nardin, and Monica Verdoia
- Subjects
ageing ,ST-segment elevation myocardial infarction ,COVID-19 ,Medicine - Abstract
Background: The constraints in the management of patients with ST-segment elevation myocardial infarction (STEMI) during the COVID-19 pandemic have been suggested to have severely impacted mortality levels. The aim of the current analysis is to evaluate the age-related effects of the COVID-19 pandemic on mechanical reperfusion and 30-day mortality for STEMI within the registry ISACS-STEMI COVID-19. Methods: This retrospective multicenter registry was performed in high-volume PPCI centers on four continents and included STEMI patients undergoing PPCI in March–June 2019 and 2020. Patients were divided according to age (< or ≥75 years). The main outcomes were the incidence and timing of PPCI, (ischemia time longer than 12 h and door-to-balloon longer than 30 min), and in-hospital or 30-day mortality. Results: We included 16,683 patients undergoing PPCI in 109 centers. In 2020, during the pandemic, there was a significant reduction in PPCI as compared to 2019 (IRR 0.843 (95%-CI: 0.825–0.861, p < 0.0001). We found a significant age-related reduction (7%, p = 0.015), with a larger effect on elderly than on younger patients. Furthermore, we observed significantly higher 30-day mortality during the pandemic period, especially among the elderly (13.6% vs. 17.9%, adjusted HR (95% CI) = 1.55 [1.24–1.93], p < 0.001) as compared to younger patients (4.8% vs. 5.7%; adjusted HR (95% CI) = 1.25 [1.05–1.49], p = 0.013), as a potential consequence of the significantly longer ischemia time observed during the pandemic. Conclusions: The COVID-19 pandemic had a significant impact on the treatment of patients with STEMI, with a 16% reduction in PPCI procedures, with a larger reduction and a longer delay to treatment among elderly patients, which may have contributed to increase in-hospital and 30-day mortality during the pandemic.
- Published
- 2023
- Full Text
- View/download PDF
38. Primary Tumor Location and Outcomes After Cytoreductive Surgery and Intraperitoneal Chemotherapy for Peritoneal Metastases of Colorectal Origin
- Author
-
Adileh, Mohammad, Yuval, Jonathan B., Walch, Henry S., Chatila, Walid K., Yaeger, Rona, Garcia-Aguilar, Julio, Schultz, Nikolaus, Paty, Philip B., Cercek, Andrea, and Nash, Garrett M.
- Published
- 2021
- Full Text
- View/download PDF
39. Impact of COVID-19 pandemic and diabetes on mechanical reperfusion in patients with STEMI: insights from the ISACS STEMI COVID 19 Registry
- Author
-
Giuseppe De Luca, Miha Cercek, Lisette Okkels Jensen, Marija Vavlukis, Lucian Calmac, Tom Johnson, Gerard Roura i Ferrer, Vladimir Ganyukov, Wojtek Wojakowski, Clemens von Birgelen, Francesco Versaci, Jurrien Ten Berg, Mika Laine, Maurits Dirksen, Gianni Casella, Petr Kala, José Luis Díez Gil, Victor Becerra, Ciro De Simone, Xavier Carrill, Alessandra Scoccia, Arpad Lux, Tomas Kovarnik, Periklis Davlouros, Gabriele Gabrielli, Xacobe Flores Rios, Nikola Bakraceski, Sébastien Levesque, Vincenzo Guiducci, Michał Kidawa, Lucia Marinucci, Filippo Zilio, Gennaro Galasso, Enrico Fabris, Maurizio Menichelli, Stephane Manzo, Gianluca Caiazzo, Jose Moreu, Juan Sanchis Forés, Luca Donazzan, Luigi Vignali, Rui Teles, Francisco Bosa Ojeda, Heidi Lehtola, Santiago Camacho-Freiere, Adriaan Kraaijeveld, Ylitalo Antti, Marco Boccalatte, Iñigo Lozano Martínez-Luengas, Bruno Scheller, Dimitrios Alexopoulos, Giuseppe Uccello, Benjamin Faurie, Alejandro Gutierrez Barrios, Bor Wilbert, Giuliana Cortese, Raul Moreno, Guido Parodi, Elvin Kedhi, and Monica Verdoia
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Background It has been suggested the COVID pandemic may have indirectly affected the treatment and outcome of STEMI patients, by avoidance or significant delays in contacting the emergency system. No data have been reported on the impact of diabetes on treatment and outcome of STEMI patients, that was therefore the aim of the current subanalysis conducted in patients included in the International Study on Acute Coronary Syndromes–ST Elevation Myocardial Infarction (ISACS-STEMI) COVID-19. Methods The ISACS-STEMI COVID-19 is a retrospective registry performed in European centers with an annual volume of > 120 primary percutaneous coronary intervention (PCI) and assessed STEMI patients, treated with primary PCI during the same periods of the years 2019 versus 2020 (March and April). Main outcomes are the incidences of primary PCI, delayed treatment, and in-hospital mortality. Results A total of 6609 patients underwent primary PCI in 77 centers, located in 18 countries. Diabetes was observed in a total of 1356 patients (20.5%), with similar proportion between 2019 and 2020. During the pandemic, there was a significant reduction in primary PCI as compared to 2019, similar in both patients with (Incidence rate ratio (IRR) 0.79 (95% CI: 0.73–0.85, p
- Published
- 2020
- Full Text
- View/download PDF
40. Gender Difference in the Effects of COVID-19 Pandemic on Mechanical Reperfusion and 30-Day Mortality for STEMI: Results of the ISACS-STEMI COVID-19 Registry
- Author
-
Giuseppe De Luca, Stephane Manzo-Silberman, Magdy Algowhary, Berat Uguz, Dinaldo C. Oliveira, Vladimir Ganyukov, Oliver Busljetik, Miha Cercek, Lisette Okkels, Poay Huan Loh, Lucian Calmac, Gerard Roura i Ferrer, Alexandre Quadros, Marek Milewski, Fortunato Scotto di Uccio, Clemens von Birgelen, Francesco Versaci, Jurrien Ten Berg, Gianni Casella, Aaron Wong Sung Lung, Petr Kala, José Luis Díez Gil, Xavier Carrillo, Maurits Dirksen, Victor Becerra, Michael Kang-yin Lee, Dafsah Arifa Juzar, Rodrigo de Moura Joaquim, Roberto Paladino, Davor Milicic, Periklis Davlouros, Nikola Bakraceski, Filippo Zilio, Luca Donazzan, Adriaan Kraaijeveld, Gennaro Galasso, Lux Arpad, Lucia Marinucci, Vincenzo Guiducci, Maurizio Menichelli, Alessandra Scoccia, Aylin Hatice Yamac, Kadir Ugur Mert, Xacobe Flores Rios, Tomas Kovarnik, Michal Kidawa, Josè Moreu, Vincent Flavien, Enrico Fabris, Iñigo Lozano Martínez-Luengas, Marco Boccalatte, Francisco Bosa Ojeda, Carlos Arellano-Serrano, Gianluca Caiazzo, Giuseppe Cirrincione, Hsien-Li Kao, Juan Sanchis Forés, Luigi Vignali, Helder Pereira, Santiago Ordoñez, Alev Arat Özkan, Bruno Scheller, Heidi Lehtola, Rui Teles, Christos Mantis, Ylitalo Antti, João António Brum Silveira, Cesar Rodrigo Zoni, Ivan Bessonov, Giuseppe Uccello, George Kochiadakis, Dimitrios Alexopulos, Carlos E. Uribe, John Kanakakis, Benjamin Faurie, Gabriele Gabrielli, Alejandro Gutierrez Barrios, Juan Pablo Bachini, Alex Rocha, Frankie C. C. Tam, Alfredo Rodriguez, Antonia Anna Lukito, Veauthyelau Saint-Joy, Gustavo Pessah, Andrea Tuccillo, Alfonso Ielasi, Giuliana Cortese, Guido Parodi, Mohamed Abed Bouraghda, Marcia Moura, Elvin Kedhi, Pablo Lamelas, Harry Suryapranata, Matteo Nardin, and Monica Verdoia
- Subjects
gender ,ST-segment elevation myocardial infarction ,percutaneous coronary intervention ,COVID-19 ,Medicine - Abstract
Background. Several reports have demonstrated the impact of the COVID-19 pandemic on the management and outcome of patients with ST-segment elevation myocardial infarction (STEMI). The aim of the current analysis is to investigate the potential gender difference in the effects of the COVID-19 pandemic on mechanical reperfusion and 30-day mortality for STEMI patients within the ISACS-STEMI COVID-19 Registry. Methods. This retrospective multicenter registry was performed in high-volume primary percutaneous coronary intervention (PPCI) centers on four continents and included STEMI patients undergoing PPCIs in March–June 2019 and 2020. Patients were divided according to gender. The main outcomes were the incidence and timing of the PPCI, (ischemia time ≥ 12 h and door-to-balloon ≥ 30 min) and in-hospital or 30-day mortality. Results. We included 16683 STEMI patients undergoing PPCIs in 109 centers. In 2020 during the pandemic, there was a significant reduction in PPCIs compared to 2019 (IRR 0.843 (95% CI: 0.825–0.861, p < 0.0001). We did not find a significant gender difference in the effects of the COVID-19 pandemic on the numbers of STEMI patients, which were similarly reduced from 2019 to 2020 in both groups, or in the mortality rates. Compared to prepandemia, 30-day mortality was significantly higher during the pandemic period among female (12.1% vs. 8.7%; adjusted HR [95% CI] = 1.66 [1.31–2.11], p < 0.001) but not male patients (5.8% vs. 6.7%; adjusted HR [95% CI] = 1.14 [0.96–1.34], p = 0.12). Conclusions. The COVID-19 pandemic had a significant impact on the treatment of patients with STEMI, with a 16% reduction in PPCI procedures similarly observed in both genders. Furthermore, we observed significantly increased in-hospital and 30-day mortality rates during the pandemic only among females. Trial registration number: NCT 04412655.
- Published
- 2023
- Full Text
- View/download PDF
41. Impact of Smoking Status on Mortality in STEMI Patients Undergoing Mechanical Reperfusion for STEMI: Insights from the ISACS–STEMI COVID-19 Registry
- Author
-
Giuseppe De Luca, Magdy Algowhary, Berat Uguz, Dinaldo C. Oliveira, Vladimir Ganyukov, Zan Zimbakov, Miha Cercek, Lisette Okkels Jensen, Poay Huan Loh, Lucian Calmac, Gerard Roura i Ferrer, Alexandre Quadros, Marek Milewski, Fortunato Scotto D’Uccio, Clemens von Birgelen, Francesco Versaci, Jurrien Ten Berg, Gianni Casella, Aaron Wong Sung Lung, Petr Kala, José Luis Díez Gil, Xavier Carrillo, Maurits Dirksen, Victor M. Becerra-Munoz, Michael Kang-yin Lee, Dafsah Arifa Juzar, Rodrigo de Moura Joaquim, Roberto Paladino, Davor Milicic, Periklis Davlouros, Nikola Bakraceski, Filippo Zilio, Luca Donazzan, Adriaan Kraaijeveld, Gennaro Galasso, Lux Arpad, Marinucci Lucia, Guiducci Vincenzo, Maurizio Menichelli, Alessandra Scoccia, Aylin Hatice Yamac, Kadir Ugur Mert, Xacobe Flores Rios, Tomas Kovarnik, Michal Kidawa, Josè Moreu, Flavien Vincent, Enrico Fabris, Iñigo Lozano Martínez-Luengas, Marco Boccalatte, Francisco Bosa Ojeda, Carlos Arellano-Serrano, Gianluca Caiazzo, Giuseppe Cirrincione, Hsien-Li Kao, Juan Sanchis Forés, Luigi Vignali, Helder Pereira, Stephane Manzo, Santiago Ordoñez, Alev Arat Özkan, Bruno Scheller, Heidi Lehtola, Rui Teles, Christos Mantis, Ylitalo Antti, João António Brum Silveira, Rodrigo Zoni, Ivan Bessonov, Stefano Savonitto, George Kochiadakis, Dimitrios Alexopulos, Carlos E. Uribe, John Kanakakis, Benjamin Faurie, Gabriele Gabrielli, Alejandro Gutierrez Barrios, Juan Pablo Bachini, Alex Rocha, Frankie Chor-Cheung Tam, Alfredo Rodriguez, Antonia Anna Lukito, Veauthyelau Saint-Joy, Gustavo Pessah, Andrea Tuccillo, Giuliana Cortese, Guido Parodi, Mohamed Abed Bouraghda, Elvin Kedhi, Pablo Lamelas, Harry Suryapranata, Matteo Nardin, and Monica Verdoia
- Subjects
myocardial infarction ,smoking paradox ,percutaneous coronary intervention ,COVID-19 ,Medicine - Abstract
The so-called “smoking paradox”, conditioning lower mortality in smokers among STEMI patients, has seldom been addressed in the settings of modern primary PCI protocols. The ISACS–STEMI COVID-19 is a large-scale retrospective multicenter registry addressing in-hospital mortality, reperfusion, and 30-day mortality among primary PCI patients in the era of the COVID-19 pandemic. Among the 16,083 STEMI patients, 6819 (42.3%) patients were active smokers, 2099 (13.1%) previous smokers, and 7165 (44.6%) non-smokers. Despite the impaired preprocedural recanalization (p < 0.001), active smokers had a significantly better postprocedural TIMI flow compared with non-smokers (p < 0.001); this was confirmed after adjustment for all baseline and procedural confounders, and the propensity score. Active smokers had a significantly lower in-hospital (p < 0.001) and 30-day (p < 0.001) mortality compared with non-smokers and previous smokers; this was confirmed after adjustment for all baseline and procedural confounders, and the propensity score. In conclusion, in our population, active smoking was significantly associated with improved epicardial recanalization and lower in-hospital and 30-day mortality compared with previous and non-smoking history.
- Published
- 2022
- Full Text
- View/download PDF
42. Oncologic Outcomes of Salvage Abdominoperineal Resection for Anal Squamous Cell Carcinoma Initially Managed with Chemoradiation.
- Author
-
Rosen, Roni, Quezada-Diaz, Felipe F., Gönen, Mithat, Karagkounis, Georgios, Widmar, Maria, Wei, Iris H., Smith, J. Joshua, Nash, Garrett M., Weiser, Martin R., Paty, Philip B., Cercek, Andrea, Romesser, Paul B., Sanchez-Vega, Francisco, Adileh, Mohammad, Roth O'Brien, Diana, Hajj, Carla, Williams, Vonetta M., Shcherba, Marina, Gu, Ping, and Crane, Christopher
- Subjects
ABDOMINOPERINEAL resection ,SQUAMOUS cell carcinoma ,PELVIC exenteration ,LOGISTIC regression analysis ,PROGRESSION-free survival ,CHEMORADIOTHERAPY - Abstract
Background: Abdominoperineal resection (APR) has been advocated for persistent or recurrent disease after failure of chemoradiation (CRT) for anal squamous cell cancer (SCC). Treatment with salvage APR can potentially achieve a cure. This study aimed to analyze oncological outcomes for salvage APR in a recent time period at a comprehensive cancer center. Methods: A retrospective review of all patients who underwent APR for biopsy-proven persistent or recurrent anal SCC between 1 January 2007 and 31 December 2020 was performed. Patients with stage IV disease at the time of initial diagnosis and patients with missing data were excluded. Univariate analysis was used with a chi-square test for categorical variables, and non-parametric tests were used for continuous variables. Kaplan–Meier survival analysis was performed to evaluate disease-specific (DSS), post-APR local recurrence-free (RFS), and disease-free survival (DFS). Results: A total of 96 patients were included in the analysis: 39 (41%) with persistent disease and 57 (59%) with recurrent SCC after chemoradiation had been completed. The median follow-up was 22 months (IQR 11–47). Forty-nine patients (51%) underwent extended APR and/or pelvic exenteration. Eight (8%) patients developed local recurrence, 30 (31%) developed local and distant recurrences, and 16 (17%) developed distant recurrences alone. The 3-year DSS, post-APR local recurrence-free survival, and disease-free survival were 53.8% (95% CI 43.5–66.5%), 54.5% (95% CI 44.4–66.8%), and 26.8% (95% CI 18.6–38.7%), respectively. In multivariate logistic regression analysis, positive microscopic margin (OR 10.0, 95% CI 2.16–46.12, p = 0.003), positive nodes in the surgical specimen (OR 9.19, 95% CI 1.99–42.52, p = 0.005), and lymphovascular invasion (OR 2.61 95% CI 1.05–6.51, p = 0.04) were associated with recurrence of disease. Gender, indication for APR (recurrent vs. persistent disease), HIV status, extent of surgery, or type of reconstruction did not influence survival outcomes. Twenty patients had targeted tumor-sequencing data available. Nine patients had PIK3CA mutations, seven of whom experienced a recurrence. Conclusions: Salvage APR for anal SCC after failed CRT was associated with poor disease-specific survival and low recurrence-free survival. Anal SCC patients undergoing salvage APR should be counseled that microscopic positive margins, positive lymph nodes, or the presence of lymphovascular invasion in the APR specimen are prognosticators for disease relapse. Our results accentuate the necessity for additional treatment strategies for the ongoing treatment challenge of persistent or recurrent anal SCC after failed CRT. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
43. Concordance in Oncogenic Alterations Between the Primary Tumor and Advanced Disease: Insights Into the Heterogeneity of Intrahepatic Cholangiocarcinoma.
- Author
-
McIntyre, Sarah M., Preston, William A., Walch, Henry, Sharib, Jeremy, Kundra, Ritika, Sigel, Carlie, Lidsky, Michael E., Allen, Peter J., Morse, Michael A., Chen, Wei, Cercek, Andrea, Harding, James J., Abou-Alfa, Ghassan K., O'Reilly, Eileen M., Park, Wungki, Balachandran, Vinod P., Drebin, Jeffrey, Soares, Kevin C., Wei, Alice, and Kingham, T. Peter
- Subjects
CHOLANGIOCARCINOMA ,HETEROGENEITY ,EXPOSURE therapy ,NUCLEOTIDE sequencing ,DISEASE progression - Abstract
PURPOSE: Intrahepatic cholangiocarcinoma (ICCA) is characterized by significant phenotypic and clinical heterogeneities and poor response to systemic therapy, potentially related to underlying heterogeneity in oncogenic alterations. We aimed to characterize the genomic heterogeneity between primary tumors and advanced disease in patients with ICCA. METHODS: Biopsy-proven CCA specimens (primary tumor and paired advanced disease [metastatic disease, progressive disease on systemic therapy, or postoperative recurrence]) from two institutions were subjected to targeted next-generation sequencing. Overall concordance (oncogenic driver mutations, copy number alterations, and fusion events) and mutational concordance (only oncogenic mutations) were compared across paired samples. A subgroup analysis was performed on the basis of exposure to systemic therapy. Patients with extrahepatic CCA (ECCA) were included as a comparison group. RESULTS: Sample pairs from 65 patients with ICCA (n = 54) and ECCA (n = 11) were analyzed. The median time between sample collection was 19.6 months (range, 2.7-122.9). For the entire cohort, the overall oncogenic concordance was 49% and the mutational concordance was 62% between primary and advanced disease samples. Subgroup analyses of ICCA and ECCA revealed overall/mutational concordance rates of 47%/58% and 60%/84%, respectively. Oncogenic concordance was similarly low for pairs exposed to systemic therapy between sample collections (n = 50, 53% overall, 68% mutational). In patients treated with targeted therapy for IDH1/2 alterations (n = 6) or FGFR2 fusions (n = 3), there was 100% concordance between the primary and advanced disease specimens. In two patients, FGFR2 (n = 1) and IDH1 (n = 1) alterations were detected de novo in the advanced disease specimens. CONCLUSION: The results reflect a high degree of heterogeneity in ICCA and argue for reassessment of the dominant driver mutations with change in disease status. The low concordance between primary and recurrent/metastatic IHC reflects a high degree of genomic heterogeneity. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
44. Case-Based Clinical Guidance on Dosing and Management of the Hepatic Artery Infusion Chemotherapy Pump.
- Author
-
Rao, Devika, Ellis, Carleton S., Kemeny, Nancy, and Cercek, Andrea
- Subjects
HEPATIC artery ,REFERENCE values ,MEDICAL equipment reliability ,LIVER tumors ,INTRAVENOUS therapy ,BODY weight ,CANCER chemotherapy ,MAGNETIC resonance imaging ,MEDICAL protocols ,DRUG infusion pumps ,PRODUCT design ,PHARMACEUTICAL arithmetic ,HEPATOTOXICOLOGY ,FLUORODEOXYURIDINE ,ABDOMINAL pain - Abstract
Hepatic artery infusion (HAI) delivers localized high-dose floxuridine directly to liver tumors through an implanted pump. While patients are undergoing active treatment, the pump is refilled with chemotherapy alternating with saline every 2 weeks using a specialized noncoring needle. Numerous clinical scenarios influence the dosing of floxuridine, which do not conform to the usual dose modification schema for systemic chemotherapy. This article aims to provide practical clinical management solutions to overcome the common challenges faced by oncologists in the real-world management of HAI pump therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
45. Factors Associated With Premature Ovarian Insufficiency in Young Women With Locally Advanced Rectal Cancer Treated With Pelvic Radiation Therapy
- Author
-
Lara Hilal, MD, Andrea Cercek, MD, John Navilio, CMD, Meier Hsu, MS, Zhigang Zhang, PhD, Paul Brady, BS, Abraham J. Wu, MD, Marsha Reyngold, MD, PhD, John J. Cuaron, MD, Paul B. Romesser, MD, Melissa Zinovoy, MD, Maliha Nusrat, MD, MS, Emmanouil Pappou, MD, PhD, FACS, FASCRS, Maria LaGratta, MD, Julio Garcia-Aguilar, MD, PhD, Philip Paty, MD, Nadeem Abu-Rustum, MD, FACOG, FACS, Mario M. Leitao, MD, FACOG, FACS, Christopher H. Crane, MD, and Carla Hajj, MD
- Subjects
Medical physics. Medical radiology. Nuclear medicine ,R895-920 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Purpose: Pelvic radiation therapy (RT) is standard of care for patients with locally advanced rectal cancer (LARC). Premature ovarian insufficiency (POI) in premenopausal women is a possible side effect. The purpose of our study was to evaluate factors associated with POI in women younger than 50 years, treated with pelvic RT for LARC, including those who underwent ovarian transposition (OT). Methods and Materials: We retrospectively reviewed the records of women younger than 50 years treated with pelvic RT for LARC at our institution between 2001 and 2019. Clinical and hormonal data were used to determine ovarian function. The ovaries and uterus were contoured and dose volume histograms were generated. Association of clinical and dosimetric factors with POI within 12 months of RT was evaluated using Wilcoxon-rank sum test and Fisher's exact test. Results: We identified 76 premenopausal women at time of RT with median age of 43 years (range, 20-49). Twenty-six women (34%) underwent OT. Neoadjuvant, concurrent, and adjuvant chemotherapy was administered in 56 (74%), 69 (91%), and 26 (34%) women, respectively. Median RT dose was 50 Gy/25 fractions. Among 75 women with 12 months of follow-up, 25% had preservation of ovarian function, all in the OT group. Ovarian function was preserved in 19 (76%) women who underwent OT. The median of ovarian mean dose was 1.7 Gy in the OT group versus 44.8 Gy in the non-OT group (P < .001). OT and age at RT were significantly associated with POI (P < .001). No patient with ovarian mean dose less than 1.36 Gy developed POI. Conclusions: OT was significantly associated with reduced risk of POI by enabling lower radiation doses to the ovaries. OT should be considered in young patients undergoing pelvic RT. Although there appears to be a significant association between ovarian mean dose and POI, larger studies are needed to find a dosimetric threshold. Our results suggest keeping the dose to the ovaries as low as reasonably achievable in patients who undergo OT and pelvic RT.
- Published
- 2022
- Full Text
- View/download PDF
46. Genomic stratification beyond Ras/B‐Raf in colorectal liver metastasis patients treated with hepatic arterial infusion
- Author
-
J. Joshua Smith, Walid K. Chatila, Francisco Sanchez‐Vega, Jashodeep Datta, Louise C. Connell, Bryan C. Szeglin, Azfar Basunia, Taryn M. Boucher, Haley Hauser, Isaac Wasserman, Chao Wu, Andrea Cercek, Jaclyn F. Hechtman, Chris Madden, William R. Jarnagin, Julio Garcia‐Aguilar, Michael I. D'Angelica, Rona Yaeger, Nikolaus Schultz, and Nancy E. Kemeny
- Subjects
colorectal cancer ,floxuridine ,implantable infusion pumps ,liver ,metastasis ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Resection of colorectal liver metastases (CLM) can cure disease, but many patients with extensive disease cannot be fully resected and others recur following surgery. Hepatic arterial infusion (HAI) chemotherapy can convert extensive liver disease to a resectable state or decrease recurrence risk, but response varies and no biomarkers currently exist to identify patients most likely to benefit. Methods We performed a retrospective cohort study of CLM patients receiving HAI chemotherapy whose tumors underwent MSK‐IMPACT sequencing. The frequency of oncogenic alterations and their association with overall survival (OS) and objective response rate were analyzed at the individual gene and signaling pathway levels. Results Three hundred and seventy patients met inclusion criteria: 189 (51.1%) who underwent colorectal liver metastasectomy followed by HAI + systemic therapy (Adjuvant cohort), and 181 (48.9%) with unresectable CLM (Metastatic cohort) who received HAI + systemic therapy, consisting of 63 (34.8%) with extrahepatic disease and 118 (65.2%) with liver‐restricted disease. Genomic alterations were similar in each cohort, and no individual gene or pathway was significantly associated with objective response. Patients in the adjuvant cohort with concurrent Ras/B‐Raf alteration and SMAD4 inactivation had worse prognosis while in the metastatic cohort patients with co‐alteration of Ras/B‐Raf and TP53 had worse OS. Similar findings were observed in a validation cohort. Conclusions Concurrently altered Ras/B‐Raf and SMAD4 mutations were associated with worse survival in resectable patients, while concurrent Ras/B‐Raf and TP53 alterations were associated with worse survival in unresectable patients. The mutual exclusivity of Ras/B‐Raf, SMAD4, and TP53 may have prognostic value for CLM patients receiving HAI.
- Published
- 2019
- Full Text
- View/download PDF
47. Evolution of surgical management of gallbladder carcinoma and impact on outcome: results from two decades at a single-institution
- Author
-
Creasy, John M., Goldman, Debra A., Gonen, Mithat, Dudeja, Vikas, O'Reilly, Eileen M., Abou-Alfa, Ghassan K., Cercek, Andrea, Harding, James J., Balachandran, Vinod P., Drebin, Jeffrey A., Allen, Peter J., Kingham, T.P., D'Angelica, Michael I., and Jarnagin, William R.
- Published
- 2019
- Full Text
- View/download PDF
48. A Summary of the Fight Colorectal Cancer Working Meeting: Exploring Risk Factors and Etiology of Sporadic Early-Age Onset Colorectal Cancer
- Author
-
Dwyer, Andrea J., Murphy, Caitlin C., Boland, C. Richard, Garcia, Reese, Hampel, Heather, Limburg, Paul, Lowery, Jan, Zauber, Ann G., Waring, Stephen, Worrall, Sharyn, Perea, Jose, Siegel, Rebecca, Lee, Jeffrey, Molmenti, Christine, Sears, Cynthia L., Buckhaults, Phillip, Hayes, Richard, Hussan, Hisham, de Miranda, Noel, Palles, Claire, Diaz, Luis, Song, Mingyang, Cercek, Andrea, Lieu, Christopher H., Patel, Swati G., Karlitz, Jordan J., Cao, Yin, Demb, Josh, Blatchford, Patrick, Risendal, Betsy, Staples, Elsa S., Wali, Anil, Daschner, Phil, Loomans-Kropp, Holli, Flores, R., Levell, Caleb L., Wehling, Karen, Martin, Jessica, Pesmen, Curt, Kuchar, Violet, Soisson, Ryan, Davis, Anjee, and Ahnen, Dennis
- Published
- 2019
- Full Text
- View/download PDF
49. Renin-angiotensin system inhibitors and mortality among diabetic patients with STEMI undergoing mechanical reperfusion during the COVID-19 pandemic
- Author
-
Giuseppe De Luca, Matteo Nardin, Magdy Algowhary, Berat Uguz, Dinaldo C Oliveira, Vladimir Ganyukov, Zan Zimbakov, Miha Cercek, Lisette Okkels Jensen, Poay Huan LOH, Lucian Calmac, Gerard Roura Ferrer, Alexandre Quadros, Marek Milewski, Fortunato Scotto di Uccio, Clemens von Birgelen, Francesco Versaci, Jurrien Ten Berg, Gianni Casella, Aaron Wong Sung Lung, Petr Kala, José Luis Díez Gil, Xavier Carrillo, Maurits Dirksen, Victor M. Becerra-Munoz, Michael Kang-yin Lee, Dafsah Arifa Juzar, Rodrigo de Moura Joaquim, Roberto Paladino, Davor Milicic, Periklis Davlouros, Nikola Bakraceski, Filippo Zilio, Luca Donazzan, Adriaan Kraaijeveld, Gennaro Galasso, Arpad Lux, Lucia Marinucci, Vincenzo Guiducci, Maurizio Menichelli, Alessandra Scoccia, Aylin Hatice Yamac, Kadir Ugur Mert, Xacobe Flores Rios, Tomas Kovarnik, Michal Kidawa, Josè Moreu, Vincent Flavien, Enrico Fabris, Iñigo Lozano Martínez-Luengas, Marco Boccalatte, Francisco Bosa Ojeda, Carlos Arellano-Serrano, Gianluca Caiazzo, Giuseppe Cirrincione, Hsien-Li Kao, Juan Sanchis Forés, Luigi Vignali, Helder Pereira, Stephane Manzo, Santiago Ordoñez, Alev Arat Özkan, Bruno Scheller, Heidi Lehtola, Rui Teles, Christos Mantis, Ylitalo Antti, João António Brum Silveira, Rodrigo Zoni, Ivan Bessonov, Stefano Savonitto, George Kochiadakis, Dimitrios Alexopulos, Carlos E Uribe, John Kanakakis, Benjamin Faurie, Gabriele Gabrielli, Alejandro Gutierrez Barrios, Juan Pablo Bachini, Alex Rocha, Frankie Chor-Cheung Tam, Alfredo Rodriguez, Antonia Anna Lukito, Veauthyelau Saint-Joy, Gustavo Pessah, Andrea Tuccillo, Giuliana Cortese, Guido Parodi, Mohammed Abed Bouraghda, Elvin Kedhi, Pablo Lamelas, Harry Suryapranata, and Monica Verdoia
- Subjects
Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
Background: During the coronavirus disease 2019 (COVID-19) pandemic, concerns have been arisen on the use of renin-angiotensin system inhibitors (RASI) due to the potentially increased expression of Angiotensin-converting-enzyme (ACE)2 and patient's susceptibility to SARS-CoV2 infection. Diabetes mellitus have been recognized favoring the coronavirus infection with consequent increase mortality in COVID-19. No data have been so far reported in diabetic patients suffering from ST-elevation myocardial infarction (STEMI), a very high-risk population deserving of RASI treatment. Methods: The ISACS-STEMI COVID-19 registry retrospectively assessed STEMI patients treated with primary percutaneous coronary intervention (PPCI) in March/June 2019 and 2020 in 109 European high-volume primary PCI centers. This subanalysis assessed the prognostic impact of chronic RASI therapy at admission on mortality and SARS-CoV2 infection among diabetic patients. Results: Our population is represented by 3812 diabetic STEMI patients undergoing mechanical reperfusion, 2038 in 2019 and 1774 in 2020. Among 3761 patients with available data on chronic RASI therapy, between those ones with and without treatment there were several differences in baseline characteristics, (similar in both periods) but no difference in the prevalence of SARS-CoV2 infection (1.6% vs 1.3%, respectively, p = 0.786). Considering in-hospital medication, RASI therapy was overall associated with a significantly lower in-hospital mortality (3.3% vs 15.8%, p
- Published
- 2021
- Full Text
- View/download PDF
50. Adjuvant Hepatic Arterial Infusion Pump Chemotherapy After Resection of Colorectal Liver Metastases: Results of a Safety and Feasibility Study in The Netherlands
- Author
-
Buisman, Florian E., Grünhagen, Dirk J., Homs, Marjolein Y. V., Grootscholten, Cecile, Filipe, Wills F., Kemeny, Nancy E., Cercek, Andrea, D’Angelica, Micheal I., Donswijk, Maarten L., van Doorn, Leni, Emmering, Jasper, Jarnagin, William R., Kingham, T. Peter, Klompenhouwer, Elisabeth G., Kok, Niels F. M., Kuiper, Maria C., Moelker, Adriaan, Prevoo, Warner, Versleijen, Michelle W. J., Verhoef, Cornelis, Kuhlmann, Koert F. D., and Groot Koerkamp, Bas
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.